Sorafenib is a multikinase inhibitor belonging to the diaryl urea class, approved for the treatment of advanced hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid cancer. By targeting… Read more




































Sorafenib is a multikinase inhibitor belonging to the diaryl urea class, approved for the treatment of advanced hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid cancer. By targeting signaling pathways such as VEGFR, PDGFR, and Raf kinases, the drug effectively inhibits tumor angiogenesis and cell proliferation. This category encompasses a comprehensive range of Sorafenib reference standards, including pharmacopeial and non-pharmacopeial impurities, synthetic metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these materials for critical tasks such as impurity profiling, the development and validation of analytical methods, and routine quality control. By integrating these precise standards into analytical workflows, researchers can ensure the accurate identification and quantification of related substances, ensuring compliance with strict regulatory safety and efficacy requirements. These compounds remain essential for monitoring degradation and supporting the rigorous analytical testing necessary throughout the drug development lifecycle.